Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 127,242

Document Document Title
WO/2017/209106A1
The present invention provides a novel oral composition of a single or twice daily dose type, which contains tipepidine or a pharmaceutically acceptable salt thereof, wherein the drug dissolution rate of tipepidine or the pharmaceuticall...  
WO/2017/209156A1
To provide a novel brain function improving agent. Provided is a brain function improving agent that comprises, as an active ingredient, Bifidobacterium breve and/or a culture containing Bifidobacterium breve.  
WO/2017/208868A1
The purpose of the present invention is to provide a pharmaceutical composition and a food which have the effect of preventing central nervous system diseases and inhibiting the advancement thereof. This pharmaceutical composition, which...  
WO/2017/208172A1
The present invention relates to a composition for use as a medicament, in the form of a gel with characteristics of a reversible thermogel, based on one or more poloxamers, water and optionally excipients, and an effective amount of an ...  
WO/2017/208072A3
Cannabinoid containing pharmaceutical compositions suitable for nasal administration are disclosed. The compositions comprise the aforementioned cannabinoids and excipients selected such that the compositions are semi-solid or viscous li...  
WO/2017/210278A1
Disclosed herein are anti-RGMa antibodies and methods of using these antibodies to treat spinal cord injury, including promoting axonal regeneration, functional recovery, or both and to treat pain, including neuropathic pain arising from...  
WO/2017/208869A1
The purpose of the present invention is to provide a pharmaceutical composition and a food which have the effect of preventing central nervous system diseases and inhibiting the advancement thereof. This pharmaceutical composition is use...  
WO/2017/208251A1
The present invention relates to a new crystalline polymorph of brexpiprazole. More specifically, the invention relates to novel Form M of brexpiprazole, process for preparing the novel form of brexpiprazole and pharmaceutical formulatio...  
WO/2017/206924A1
Provided are a compound as represented by structural formula (I) ({5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-6-aminopyri dazin-3-yl}-N-{4-[((3S,5R)-3,5-dimethylpiperazinyl)carbonyl] phenyl}carboxamide hydrochloride) and a novel crys...  
WO/2017/208088A3
The invention relates to the compounds of formula (I), formula (II) and formula (III) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositio...  
WO/2017/209267A1
The present invention provides a novel compound having a P2X3 and/or P2X2/3 receptor antagonistic activity. A compound represented by formula (I) (wherein R1a represents a substituted or unsubstituted alkyl group or the like; R1b represe...  
WO/2017/208267A1
The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is –NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon...  
WO/2017/210545A1
Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided...  
WO/2017/208867A1
The purpose of the present invention is to provide a pharmaceutical composition and a food which have the effect of preventing central nervous system diseases and inhibiting the advancement thereof. This pharmaceutical composition, which...  
WO/2017/208069A2
The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when ...  
WO/2017/210343A1
In some embodiments herein, methods, compositions, and uses for modulating lymphatic vessels of the central nervous system are described. In some embodiments, methods, compositions, or uses for treating, preventing, or ameliorating sympt...  
WO/2017/209027A1
Provided is a novel autophagy-inducing agent. The autophagy-inducing agent comprises, as an active ingredient, an ingredient selected from among adefovir dipivoxil, azidothymidine, benproperine, cloperastine, enalapril, homochlorcyclizin...  
WO/2017/209265A1
Provided are: a novel compound having P2X7 receptor inhibitory activity; and a pharmaceutical composition having P2X7 receptor inhibitory activity. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (In ...  
WO/2017/210668A1
Disclosed herein are methods and compositions for sustained release of kappa-opioid agonists. The modified kappa-opioid agonists disclosed herein exhibit high peripheral to CNS selectivity, and benefits patients with visceral and neuropa...  
WO/2017/202376A1
A sulfamide compound and a use thereof in preparing pain killers, which specifically relates to compounds as shown in formula (I) and formula (II), tautomers thereof or pharmaceutically acceptable salts thereof.  
WO/2017/202360A1
A tetradentate chelating monoquinoline derivative as represented by formula (I). The derivative can specifically chelate to a redox-active metal ion, such as a copper ion, related to a neurodegenerative disease (Alzheimer's disease, Park...  
WO/2017/204618A1
The present invention provides a composition for preventing or mitigating dementia in a subject comprising a mixture of tocotrienols, tocopherol, squalene and B vitamin, and a pharmaceutically acceptable carrier.  
WO/2017/204318A1
Provided is a novel compound having an antagonism to P2X3 and/or P2X2/3 receptors. A compound represented by formula (I) [wherein: R1 represents an optionally substituted alkyl group, etc.; R2 represents an optionally substituted aromati...  
WO/2017/202206A1
The present invention discloses a substituted quinoline compound as shown in formula (I), a pharmaceutical composition comprising said compound or a polymorph, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, an isotopic va...  
WO/2017/204166A1
Provided is a means for treating and/or preventing a peripheral nerve disorder through promotion of regeneration of peripheral nerves. More specifically, provided is a composition for treatment and/or prevention of a peripheral nerve dis...  
WO/2017/202365A1
Provided are a preparation method for a trifluoromethyl-substituted pyran derivative and an intermediate thereof, namely, a preparation method for a compound as shown in formula (I) and an intermediate thereof. The method is characterize...  
WO/2017/204277A1
The present invention provides an anti-TGF-beta3 antibody and a method of using the antibody. The anti-TGF-beta3 antibody according to the present invention has a binding activity to TGF-beta3 but does not have a neutralizing activity to...  
WO/2017/204316A1
The present invention provides a novel compound having P2X3 and/or P2X2/3 receptor antagonism. A compound represented by formula (I): (wherein, R1 represents a substituted or unsubstituted alkyl or the like, R2 represents a substituted o...  
WO/2017/202394A1
A fusion protein used for preventing and treating Alzheimer's disease, a preparation method therefor, and an application thereof. The fusion protein comprises the extracellular domain of human p75NTR (p75 neurotrophin receptor) (p75NTR-E...  
WO/2017/205393A1
The present disclosure describes compositions and methods for treating at least one negative symptom in a human subject who does not have a clinical diagnosis of schizophrenia. The compositions and methods employ a therapeutically effect...  
WO/2017/202266A1
The present invention relates to a 2-amino-3-substituted mercaptopropionate derivative, a preparation method therefor and a use thereof. The 2-amino-3-substituted mercaptopropionate derivative according to the present invention has a str...  
WO/2017/204619A1
The present invention provides an aqueous extract of Andrographis paniculata leaves containing as main components andrographolide, neoandrographolide and 14-deoxy-11,12-didehydroandrographolide. The Invention also provides a method of pr...  
WO/2017/201712A1
Disclosed is a use of a nootkatone in the preparation of medicines for preventing and/or treating depression.The nootkatone has a significant efficacy which is better than that of the existing antidepressant drug Prozac; and it has a wid...  
WO/2017/202424A1
A powdered composition is disclosed, the powdered composition comprising a complex between one or more cannabinoids having at least one phenolic moiety and a basic ion exchange resin. Also, an orally dispensable delivery vehicle, a metho...  
WO/2017/202814A1
The present invention relates to methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons. The 10 inventors showed that interleukin 33 promotes axonal outgrowth ...  
WO/2017/204210A1
Provided is an oral pharmaceutical composition characterized by containing a medicinal ingredient (A), a hydrophobic liquid (B), a water-soluble macromolecular substance (C), and an excipient (D), but not containing a surfactant, wherein...  
WO/2017/205399A1
The present disclosure describes compositions and methods for treating at least one symptom of an anxiety disorder in a human subject. The compositions and methods employ a therapeutically effective amount of a compound of formula I (Com...  
WO/2017/201581A1
The present invention relates to new desferrioxamine B-based compounds that may be useful to treat neurodegenerative diseases, to their preparation, and to compositions including the compounds. The present invention also relates to the u...  
WO/2017/204231A1
In brain dysfunction induced by brain hemorrhage or ischemia, it is needed to treat causative disease, i.e., hemorrhage or ischemia, and it is also needed to promote the protection or regeneration of nerve cells or the like that are dama...  
WO/2017/204321A1
The present invention provides a heat shock protein expression inducing agent, more specifically, a heat shock protein expression inducing agent containing a compound represented by formula (I) or a salt thereof. (In the formula, R repre...  
WO/2017/199042A1
The present invention provides an inhibitor of DNA damage signalling and repair for use in treating or preventing a neurological pathology and a neuro-regenerative compound comprising an inhibitor of DNA damage signalling and repair atta...  
WO/2017/199070A1
The present invention relates to a combination of pure 5-HT6 receptor antagonist, acetylcholinesterase inhibitor and NMDA receptor antagonist. Also, the present invention provides pure 5-HT6 receptor (5-HT6R) antagonists, or the pharmace...  
WO/2017/201069A1
The present invention provides chimeric compounds of formula (II) that modulate protein function, to restore protein homeostasis, including cytokine, aiolos, and/or ikaros activity, TNF-alpha activity, CKl-alpha activity and cell-cell ad...  
WO/2017/200953A1
Disclosed herein are methods for treating a human subject having a disease associated with an increased level of apoptosis using a nitroxide. Further disclosed are methods for treating a human subject in need of a reduced expression leve...  
WO/2017/199755A1
Provided is a drug that has excellent effect of preventing and/or treating dementia. The drug comprises a carbostyril derivative represented by formula (1) [wherein: R represents a cycloalkyl group; A represents a lower alkyl group; and ...  
WO/2017/201283A1
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally available formulations and other phar...  
WO/2017/197791A1
A Radix Polygoni Multiflori and Fructus Lycii liquor, consisting of the components of: 150 g of Radix Polygoni Multiflori, 80 g of Radix Rehmanniae Preparata, 100 g of Fructus Lycii, 30g Rhizoma Polygonati, 30 g of Radix Angelicae Sinens...  
WO/2017/198346A1
The present invention is relates to a compound of formula (I), wherein X1, X2 andX3 are, independently of each other, N or CH; with the proviso that at least two of X1X2andX3 areN; Y is N or CH; R1 and R2 are independently of each other ...  
WO/2017/198224A1
Provided is a pharmaceutical composition of remimazolam. In particular, provided is a pharmaceutical composition comprising remimazolam or a pharmaceutically acceptable salt thereof and a hydroxyethyl starch and/or a monosaccharide compo...  
WO/2017/199140A1
The invention relates to a method and a pharmaceutical composition of a combination of tramadol-etoricoxib hydrochloride for the treatment of pain, the production method of which is based on two active ingredients consisting of granules ...  

Matches 101 - 150 out of 127,242